Policy Trends - Recent COVID-19 infections show a slight increase in some regions, but the clinical severity has not changed significantly according to a Chinese CDC expert [2] Drug and Device Approvals - Changshan Pharmaceutical's nadroparin calcium injection has received a drug registration certificate from Belarus, used for treating venous thromboembolism and other related conditions [3] - Shanghai Pharmaceuticals announced that its rivaroxaban tablets have received approval from the US FDA, aimed at reducing the risk of stroke and systemic embolism in non-valvular atrial fibrillation patients, among other uses [4] Capital Markets - Shanghai Kejun Pharmaceutical Technology Co., Ltd. completed a B+ round financing exceeding 100 million yuan, with funds primarily allocated for the phase III clinical development of its core product CG-0255 in the cardiovascular field [5] Industry Developments - Jingyin Pharmaceutical and CRISPR Therapeutics have formed a strategic partnership to jointly develop and commercialize a long-acting siRNA therapy for thrombotic diseases [6] - Buchang Pharmaceutical's subsidiary signed a commissioned research agreement with Fubicheng Pharmaceutical for the development of MF59 adjuvant [7] - Sanofi and Pfizer entered into a licensing agreement for a bispecific antibody product targeting PD-1 and VEGF, with Pfizer gaining exclusive rights outside mainland China [9] Public Sentiment Alerts - Jinhua Co., Ltd. reported that shareholder Xinyu Jinyu has reduced its holdings by 133,500 shares, representing 0.035765% of the company's total share capital [10] - Fosun Pharma announced the resignation of its Senior Vice President Rong Yang for personal reasons, effective May 16, 2025 [11]

Group 1 - Shanghai Pharmaceuticals has received FDA approval for its abbreviated new drug application (ANDA) for Rivaroxaban tablets [1] - Rivaroxaban is indicated for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) [1][2] - The company has invested approximately RMB 8.2 million in the research and development of Rivaroxaban [1] Group 2 - The market for Rivaroxaban in the U.S. generated approximately $8.13 billion in sales in 2023, with projected sales of about $6.33 billion for the first three quarters of 2024 [2] - Competitors in the U.S. market for Rivaroxaban include Janssen Pharmaceuticals and several generic manufacturers [2] Group 3 - The FDA has also approved the ANDA for Mometasone Furoate nasal spray by Zhejiang Xinyi Ruijue Pharmaceutical [4] - Mometasone Furoate is used for the prevention and treatment of seasonal allergic rhinitis in adolescents and adults, as well as for chronic sinusitis with nasal polyps in adults [5] - The nasal spray generated approximately $43.7 million in sales in the U.S. in 2023, with projected sales of about $33.45 million for the first three quarters of 2024 [5]

Core Viewpoint - The article discusses the significant impact of antitrust penalties on the financial performance of Xianju Pharmaceutical and other companies involved in price-fixing agreements for dexamethasone phosphate raw materials during the COVID-19 pandemic [1][3]. Group 1: Antitrust Penalties - Xianju Pharmaceutical was fined 195 million yuan for monopolistic practices, which accounts for 4.88% of its 2024 revenue and 49.17% of its net profit [1]. - Tianyao Pharmaceutical and Lianhuan Pharmaceutical were also penalized, with fines of 69.19 million yuan and 61.04 million yuan, respectively [1]. - The companies formed a price alliance, raising the price of dexamethasone phosphate from 0.35 yuan to a peak of 98.76 yuan, an increase of nearly 282 times [1]. Group 2: Financial Impact on Companies - In 2024, Xianju Pharmaceutical's net profit fell by 29.46% to 397 million yuan, largely due to the antitrust fine [2][4]. - The cash flow from operating activities for Xianju Pharmaceutical decreased by 33.05%, and cash reserves dropped by 16.76% [4]. - Tianyao Pharmaceutical's revenue in 2024 was 3.215 billion yuan, down 15%, but its net profit increased by 14% due to the fine being accounted for in 2025 [6][7]. Group 3: Market Adjustments and Strategies - Xianju Pharmaceutical is shifting its product structure and expanding into overseas markets to mitigate the impact of declining revenues from dexamethasone products [5]. - The company is focusing on high-margin areas such as respiratory and dermatological products, with sales in respiratory products growing by 31% in 2024 [5]. - Tianyao Pharmaceutical's steroid raw material business also saw a revenue decline of 16.9% in 2024, indicating broader market pressures [7]. Group 4: Ongoing Challenges - Tianyao Pharmaceutical has faced multiple antitrust penalties over the past four years, indicating a pattern of regulatory scrutiny [8]. - Lianhuan Pharmaceutical's future penalties remain uncertain as it plans to appeal the decision, highlighting the ongoing challenges within the industry [8].